IKT NASDAQ
Inhibikase Therapeutics, Inc.
1W: -8.2%
1M: -23.4%
3M: -29.0%
YTD: -19.5%
1Y: +1.9%
3Y: +70.7%
5Y: -86.4%
$1.57
+0.05 (+3.29%)
Pre-Market: $1.59 (+0.02, +1.27%)
Weekly Expected Move ±8.0%
$1
$1
$2
$2
$2
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 15.72.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$0M
Revenue
+0.0% YoY
$-61M
Net Income
-46.1% YoY
$-43M
Free Cash Flow
-116.4% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-52.0%
ROA-48.0%
ROIC920.5%
Valuation
P/E-3.3
P/B1.8
EV/EBITDA-3.2
Leverage
Debt/Equity0.00
Current Ratio15.82
Interest Cov.0.0x
Quality Scores
Piotroski F3/9
Altman Z19.08
Beneish M0.00